Skip to Content
 

VICC toll-free number 1-877-936-8422

Gynecologic Cancers

Vanderbilt Ingram Cancer Center's Division of Gynecologic Oncology specializes in the prevention, diagnosis and treatment of gynecologic malignancy, including ovarian cancer, cervical cancer, and endometrial cancer.

Clinical Trials for Gynecologic Cancers

7 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Ovarian

VICCGYN14123

01/06/2015

Prospective Tissue and Clinical Database for Ovarian Cancer Studies

Treatment

Kidney (Renal Cell)
Lung
Melanoma
Miscellaneous
Non Small Cell
Uterine

VICCPHI1634

08/30/2016

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

Treatment

Breast
Lung
Non Small Cell
Ovarian
Pancreatic

VICCPHI1671

08/02/2016

A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

Treatment

Colon
Head/Neck
Lung
Lymphoma
Melanoma
Non Small Cell
Ovarian
Rectal

VICCPHI1531

03/01/2016

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

Treatment

Bladder
Breast
Colon
Esophageal
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Lung
Melanoma
Non Small Cell
Pancreatic
Rectal
Urologic
Uterine

VICCPHI1588

11/27/2015

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Treatment

Gynecologic
Ovarian

VICCGYN1492

06/16/2015

A Randomized, Open-Label Study Comparing the Combination of YONDELIS? and DOXIL?/CAELYX? With DOXIL?/CAELYX? Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Treatment

Bladder
Colon
Esophageal
Gastric/Gastroesophageal
Neuro-Oncology
Ovarian
Urologic
Uterine

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification